Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL, Inc. (Nasdaq: GRAL) is a healthcare diagnostics company whose mission is to detect cancer early, when it can be cured. The company’s news flow centers on developments related to its multi-cancer early detection (MCED) blood test, Galleri, and the targeted methylation-based platform that underpins it. GRAIL regularly reports on clinical study results, commercial collaborations, capital-raising activities, and investor events, giving readers insight into how its MCED strategy is progressing.
News updates often highlight data from large clinical studies such as PATHFINDER 2 and SYMPLIFY, where GRAIL describes Galleri’s performance when added to standard-of-care screening or used in symptomatic populations. These releases provide details on cancer detection rates, positive predictive value, specificity, cancer signal origin accuracy, and safety outcomes, as well as how Galleri may detect cancers that lack recommended screening options.
Investors and healthcare observers can also find announcements about financial results, private placements, and equity distribution arrangements, which GRAIL describes as supporting its commercial and reimbursement efforts. Additional coverage includes strategic collaborations, such as agreements with Medcan and Manulife Canada for access to Galleri, and a planned collaboration with Samsung-related entities to commercialize the test in certain Asian markets, subject to regulatory and contractual conditions.
This news page aggregates these company-issued updates so readers can follow GRAIL’s reported clinical evidence, commercial partnerships, financing transactions, and conference presentations over time.
GRAIL (Nasdaq: GRAL) reported Q2 2024 financial results, showing 43% year-over-year revenue growth to $32.0 million. The company faced a net loss of $1.59 billion, including a $1.42 billion goodwill and intangible impairment. GRAIL's adjusted gross profit increased 66% to $16.0 million, while adjusted EBITDA was $(139.4) million.
Key highlights include enrollment in the REACH study, completion of PATHFINDER 2 study enrollment, and final study visits for the NHS-Galleri trial. GRAIL announced a strategic restructuring, reducing headcount by 30% and focusing on core multi-cancer early detection priorities. These measures are expected to extend the company's cash runway into 2028 and reduce burn to $325 million in 2025.
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress.
Investors and interested parties can access the live webcast and recorded replay through the investor relations section of GRAIL's website at investors.grail.com. Registration for the teleconference is available at https://grail-q2-financial-results-2024.open-exchange.net/. Participants are advised to register and join the webcast at least ten minutes before the scheduled start time to ensure timely connection.
GRAIL (Nasdaq: GRAL) has announced the enrollment of the first participant in the REACH study, evaluating the clinical impact of its Galleri® multi-cancer early detection (MCED) test in the Medicare population. The study, conducted at Community Health Network in Indiana, aims to enroll up to 50,000 Medicare beneficiaries across 50 sites, with a focus on including diverse and underrepresented populations.
The three-year study will compare participants receiving usual care plus an annual Galleri test to those receiving usual care alone. It will assess the reduction in diagnosed stage IV cancers, safety, and healthcare resource utilization associated with Galleri use. The study is FDA-approved and covered by Medicare for participants. This initiative addresses a critical need, as nearly 70% of cancer deaths in the US occur in people aged 65 and older.
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England.
Results from the first 25,000 PATHFINDER 2 participants are expected in the second half of 2025, while final results from the NHS-Galleri trial are anticipated in 2026. These studies aim to expand GRAIL's clinical validation and performance evidence for the Galleri test, with a focus on diverse participant populations. The data will support GRAIL's premarket approval application to the FDA, which is currently in process under a Breakthrough Device Designation.